
Cytely is a Swedish DeepTech company pioneering data-driven, smart microscopy technology that transforms traditional microscopy into an autonomous, intelligent system. Their platform combines advanced algorithms with real-time automated decision-making to capture high-fidelity quantitative microscopy data, enabling researchers to identify critical micro- and nano-level events with precision and speed. Cytely's solution integrates seamlessly with existing microscopes, providing ready-to-go assays and publication-ready results that accelerate research in biotech and pharmaceutical R&D. The company focuses on removing bottlenecks in microscopy workflows, enhancing reproducibility, and democratizing access to sophisticated imaging technology for advanced research teams worldwide. Their technology has demonstrated significant improvements in data throughput, imaging time reduction, and insight acceleration, positioning Cytely as a key innovator in smart microscopy for life sciences.

Cytely is a Swedish DeepTech company pioneering data-driven, smart microscopy technology that transforms traditional microscopy into an autonomous, intelligent system. Their platform combines advanced algorithms with real-time automated decision-making to capture high-fidelity quantitative microscopy data, enabling researchers to identify critical micro- and nano-level events with precision and speed. Cytely's solution integrates seamlessly with existing microscopes, providing ready-to-go assays and publication-ready results that accelerate research in biotech and pharmaceutical R&D. The company focuses on removing bottlenecks in microscopy workflows, enhancing reproducibility, and democratizing access to sophisticated imaging technology for advanced research teams worldwide. Their technology has demonstrated significant improvements in data throughput, imaging time reduction, and insight acceleration, positioning Cytely as a key innovator in smart microscopy for life sciences.
What they do: AI-driven SaaS that converts microscopy into autonomous, data‑driven workflows
Headquarters: Medicon Village, Lund / Malmö region, Sweden
Founded: 2022
Stage / funding: Pre-seed; early venture backing
Team size: Approximately 16 employees
Microscopy bottlenecks in life‑science research (manual targeting, low reproducibility, slow data throughput).
2022
Biotechnology
4022734 USD
Early venture backing; other investor listed as Ugly Duckling Ventures in available evidence
“Backed by Icebreaker.vc and other early‑stage investors”
| Company |
|---|
What We're Building
Cytely turns any fluorescence microscope into a real-time data engine. Think of it as bringing the quantitative rigor of flow cytometry to the spatial richness of microscopy—automated segmentation, per-cell gating, phagocytosis metrics, kinetic tracking—all while maintaining the "why" through interactive image browsing.
The product is technical. The science matters. The sales motion is consultative, pilot-driven, and requires genuine fluency in microscopy workflows. You can't fake it with these customers.
What You'll Actually Do
What Success Looks Like (6–12 months)
Who Thrives HereYou should join if
You should NOT join if
What You BringMust‑haves
Nice‑to‑haves
Why This Matters
Scientists are still spending months on image analysis that should take minutes. Breakthroughs are delayed because researchers can't process the data their microscopes generate. Drug targets go unexplored. Assays stay manual and irreproducible.
Cytely's vision is to close the loop from acquisition to decision on an experiment-day timescale, not a grant cycle. We want to build a global discovery system that eventually predicts outcomes and autonomously drives research.
You're not selling software. You're accelerating biomedical research that could prevent curable disease.
Practical Details
Interview Process
One Last Thing
If you're reading this and thinking 'this sounds chaotic, risky, and like a ton of work' — you're right. It is.
But if you're also thinking 'this sounds like the opportunity to build something from zero, work on a mission that matters, and prove you can create commercial leverage at a deep-tech startup before anyone else believes it's possible' — then we should talk.
We're looking for one person. The right one.